Humana Inc. (NYSE:HUM) Shares Sold by Empirical Finance LLC

Empirical Finance LLC reduced its stake in Humana Inc. (NYSE:HUM) by 1.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,276 shares of the insurance provider’s stock after selling 47 shares during the period. Empirical Finance LLC’s holdings in Humana were worth $1,085,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HUM. Creative Financial Designs Inc. ADV raised its position in Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. Ashton Thomas Securities LLC purchased a new stake in shares of Humana during the third quarter worth approximately $31,000. Your Advocates Ltd. LLP raised its holdings in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares in the last quarter. Atwood & Palmer Inc. lifted its stake in Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after acquiring an additional 60 shares during the last quarter. Finally, LRI Investments LLC grew its holdings in Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after acquiring an additional 143 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Morgan Stanley lifted their price objective on shares of Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and upped their price objective for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Piper Sandler raised their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Wells Fargo & Company lowered their price target on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Finally, TD Cowen raised their price objective on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Humana has a consensus rating of “Hold” and a consensus target price of $297.68.

Humana Stock Down 2.7 %

HUM opened at $266.91 on Tuesday. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The business has a 50 day moving average price of $274.21 and a two-hundred day moving average price of $297.52. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market cap of $32.14 billion, a PE ratio of 23.64, a P/E/G ratio of 2.11 and a beta of 0.56.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.